Lv3
330 积分 2025-01-06 加入
Efbemalenograstim Alfa: First Approval
8天前
已完结
Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis
12天前
已完结
Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo
12天前
已完结
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated by Gemcitabine-based Chemotherapy
13天前
已完结
Small molecules for Kirsten rat sarcoma viral oncogene homolog mutant cancers: Past, present, and future
20天前
已完结
Pembrolizumab plus lenvatinib in second-line and third-line patients with pleural mesothelioma (PEMMELA): a single-arm phase 2 study
21天前
已完结
Sintilimab combined with bevacizumab in relapsed or persistent ovarian clear cell carcinoma (INOVA): a multicentre, single-arm, phase 2 trial
29天前
已完结
First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
1个月前
已完结
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update
1个月前
已完结
219P Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
1个月前
已关闭
皖公网安备34019202002308
